文献速递肝病消化道肿瘤与早癌消化内镜

基于应答的肝细胞癌TACE治疗后生存预测模型

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.
PubMed 文献 · Hepatology · 2020-05-27

该研究收集11国19中心4621例接受TACE的HCC患者数据,构建包含mRECIST应答的TACE前和TACE后生存预测模型,模型预测准确性优于现有评分,可将患者分为4个风险组,中位OS从7个月至超过4年。

要点

  • 基于常规临床特征和首次TACE后应答可进行患者个体化预后评估
  • 新模型预测准确性优于HAP评分及其各种修改版
  • 模型可将患者分为4个不同风险类别,中位OS范围7个月至超过4年

核心结论

  • 基于常规临床特征和首次TACE后应答的TACE特异性模型经广泛验证,可实现患者层面的预后判断。

研究设计与样本

  • 收集11个国家19个中心4621例接受TACE治疗的HCC患者的临床相关基线参数。
  • 部分中心同时采集了按mRECIST评估的影像学应答。
  • 数据集分为训练集、内部验证集和两个外部验证集。
  • 构建了TACE前模型(Pre-TACE-Predict)和包含应答的TACE后模型(Post-TACE-Predict)。

主要发现

  • 中位总生存期(OS)为19.9个月。
  • 影响生存的因素包括肿瘤数目和大小、甲胎蛋白、白蛋白、胆红素、血管侵犯、病因以及mRECIST评估的应答。
  • 所提出的模型预测准确性优于现有模型(肝动脉栓塞预后评分及其各种修改版)。
  • 模型可将患者分为4个不同风险类别,中位OS从7个月至超过4年。

临床怎么用

  • 可利用常规临床特征和首次TACE后mRECIST应答对HCC患者进行个体化生存预测和风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The heterogeneity of intermediate-stage hepatocellular carcinoma (HCC) and the widespread use of transarterial chemoembolization (TACE) outside recommended guidelines have encouraged the development of scoring systems that predict patient survival. The aim of this study was to build and validate statistical models that offer individualized patient survival prediction using response to TACE as a variable. APPROACH AND RESULTS: Clinically relevant baseline parameters were collected for 4,621 patients with HCC treated with TACE at 19 centers in 11 countries. In some of the centers, radiological responses (as assessed by modified Response Evaluation Criteria in Solid Tumors [mRECIST]) were also accrued. The data set was divided into a training set, an internal validation set, and two external validation sets. A pre-TACE model ("Pre-TACE-Predict") and a post-TACE model ("Post-TACE-Predict") that included response were built. The performance of the models in predicting overall survival (OS) was compared with existing ones. The median OS was 19.9 months. The factors influencing survival were tumor number and size, alpha-fetoprotein, albumin, bilirubin, vascular invasion, cause, and response as assessed by mRECIST. The proposed models showed superior predictive accuracy compared with existing models (the hepatoma arterial embolization prognostic score and its various modifications) and allowed for patient stratification into four distinct risk categories whose median OS ranged from 7 months to more than 4 years. CONCLUSIONS: A TACE-specific and extensively validated model based on routinely available clinical features and response after first TACE permitted patient-level prognostication.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Han G, Berhane S, Toyoda H, et al. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Hepatology. 2020. PMID: 31698504. doi:10.1002/hep.31022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。